MaxCyte MXCT Non Us — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's non us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's non us — revenue?
- MaxCyte (MXCT) reported non us — revenue of $3.04M in Q1 2026.
- How has MaxCyte's non us — revenue changed year-over-year?
- MaxCyte's non us — revenue increased by 28.8% year-over-year, from $2.36M to $3.04M.
- What is the long-term trend for MaxCyte's non us — revenue?
- Over 2 years (2023 to 2025), MaxCyte's non us — revenue has grown at a 16.1% compound annual growth rate (CAGR), from $8.87M to $11.95M.
- What does non us — revenue mean?
- This metric represents the total revenue generated from customers and licensing agreements located outside of the company's primary domestic market. It serves as a key indicator of the company's international market penetration and the global adoption of its proprietary cell engineering platform technologies. Tracking this figure helps investors assess the geographic diversification of the business and the scalability of its commercial operations in foreign jurisdictions.